Description

Retatrutide is a novel triple-receptor agonist that targets GLP-1, GIP and glucagon receptors simultaneously. This tri-agonist approach represents an advanced area of metabolic peptide research, with studies exploring how combined receptor activation may influence glucose homeostasis, appetite signalling, lipid metabolism and energy expenditure. Research has generated considerable interest in its potential role within next-generation incretin-based metabolic investigations. Early clinical research has also examined changes in body weight and broader metabolic parameters. This 10mg × 10 vial presentation supports controlled laboratory research into multi-receptor activation, metabolic signalling and the evolving field of next-generation incretin research.